Tonghua Golden-Horse Pharmaceutical Industry Co Ltd

Tonghua Golden-Horse Pharmaceutical Industry Co Ltd maintains a debt-to-equity ratio of 0.77, indicating a moderate level of leverage, and a current ratio of 1.88, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

The company's profitability is weak, with a return on equity of 0.14% and a return on assets of 0.07%, both significantly below the typical thresholds for pharmaceutical firms, which often aim for ROE above 10% and ROA above 5%. This suggests that the company is not effectively utilizing its equity or assets to generate returns.

Tonghua Golden-Horse's revenue is concentrated in a single geographic market, China, with no disclosed international operations. The company does not provide segment-level revenue breakdowns, making it difficult to assess the performance of individual product lines or therapeutic areas.

The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections. Historical revenue data shows a static position, with no clear upward or downward trend, and no specific drivers of future growth identified in the available data.

The company faces a medium liquidity risk due to its negative net cash position and a low dilution risk, as there is no indication of imminent share issuance or dilution pressures. No adjustments have been applied to the valuation metrics, suggesting the financial data is presented without material modifications.

Recent filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The company has not disclosed any major events, such as mergers, acquisitions, or regulatory changes, that would significantly impact its operations or financial position.

Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766.SZ) has undergone a formal classification update, with its primary activity now explicitly identified as "Pharmaceuticals" within the broader "Healthcare" economic sector. This structural clarification, marked as a medium-severity change, establishes the company’s operational identity in the current analysis framework, replacing previous undefined status. Concurrently, the firm’s risk profile has been initialized with specific assessments. Dilution risk is now rated as "low," indicating a stable capital structure with minimal threat of share value erosion from new issuances. This assessment provides a baseline for evaluating shareholder equity protection. In contrast, liquidity risk has been classified as "medium." This designation suggests that while the company maintains operational viability, there may be moderate constraints or volatility in its ability to meet short-term financial obligations or trade volume expectations. This risk level warrants monitoring but does not indicate immediate distress. The synthesis of these changes—sector definition alongside low dilution and medium liquidity risks—offers a clearer, albeit preliminary, view of the company’s financial standing. With no analyst coverage, index memberships, or top holder data currently recorded, these foundational metrics serve as the primary indicators for investors assessing the firm’s current market position. [doc:000766.sz-ha-financials]

The company demonstrates best-in-class cash conversion at 11.61, significantly outperforming the pharmaceutical cohort median of 0.95.

Revenue reached CNY 1.17 billion in FY0, maintaining a substantial gross profit base of CNY 845 million despite recent declines.

The firm maintains a low dilution risk profile, suggesting current equity structure stability for existing shareholders.

The company carries a high credit risk flag, raising concerns about its ability to meet long-term debt obligations.

Operating margin of 0.86% trails the industry median of 5.45%, highlighting weak operational performance relative to peers.